View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Juan Ros-Padilla
  • Juan Ros-Padilla

Grifols B : Market watchdog sees relevant and significant deficiencies...

>Report finds deficiencies yet the company gets away with a light punishment - The Spanish market watchdog (CNMV) has finally issued its long-awaited report on Grifols’ unorthodox accounting methods. After reading it, we extract the following main conclusions: i) CNMV has found ‘relevant and significant deficiencies’ in the accounts, ii) besides pointing out the faults, the watchdog does not inquire further into what led the managers to proceed that way nor has any k...

Juan Ros-Padilla
  • Juan Ros-Padilla

Grifols B : Q4 2023 earnings below expectations. Breakeven FCF guidanc...

>Top line back to its usual cruising speed - Sales grew by +3% or +9% cc (vs +9% cc in Q3) reaching € 1.8bn, somewhat below our numbers yet more aligned with the consensus. Biopharma posted a +5% y-o-y growth or +10% cc (vs +14% cc in Q3) to € 1.5bn driven by: i/ solid plasma collection growth (+10% in FY 2023 vs +10% in 9M), ii/ IGg demand (higher Xembify demand in the US and robust IGg demand in Europe) and price upticks, iii/ AAT uptick in Q4 (+2% cc) but still im...

Juan Ros-Padilla
  • Juan Ros-Padilla

Grifols B : A matter of trust

>Gotham’s report damage, regardless of its accuracy, will take some time to repair - The report, while vague and lacking new items, has put the spotlight on Grifols’ unorthodox way of conducting M&A involving structures with related parties. Us analysts were somewhat forgiving with this, given its (apparently) undemanding valuation, its purpose of amendment (new CEO, efficiency plan, asset disposals…) and the earnings momentum. The market has shown to be far less merc...

Ahmed Ben Salem
  • Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 01/17/2024

We host our 27th ODDO BHF Forum in Lyon in 11th and 12th January 2024 and virtually 15th and 16th January 2024. In total, 335 companies will be presenting. In the following note, we provide some initial feedback of the company on the last day (day 4). - ...

Ahmed Ben Salem
  • Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 17/01/2024

We host our 27th ODDO BHF Forum in Lyon in 11th and 12th January 2024 and virtually 15th and 16th January 2024. In total, 335 companies will be presenting. In the following note, we provide some initial feedback of the company on the last day (day 4). - ...

Delphine Brault ... (+3)
  • Delphine Brault
  • Quentin Borie
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 01/09/2024

Defensives are sharply outperforming cyclicals at the start of 2024. We think investors should start to gear portfolios towards our more cautious strategic allocation for 2024, while also taking account of the likely continuation of volatility on rates. Within defensives, we prefer utilities, telecoms, personal care & grocery stores and insurance. We think that the recent sell-off for technology offers an entry point, particularly in the semiconductors segment. We remain cautious on d...

Delphine Brault ... (+3)
  • Delphine Brault
  • Quentin Borie
  • Thomas Zlowodzki

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 09/01/2024

Les défensives surperforment nettement les cycliques en ce début d’année. Nous pensons qu’il faut commencer à orienter les portefeuilles vers notre allocation stratégique 2024, plus prudente, tout en intégrant la probable poursuite de la volatilité sur les taux. Au sein des défensives, nous privilégions Utilities, Telecoms, Personal Care & Grocery Stores et Assurances. Nous considérons que la baisse récente de la Technologie est un point d’entrée, notamment sur le segment des semicond...

Juan Ros-Padilla
  • Juan Ros-Padilla

Grifols B : Our rating under review following Gotham’s report

>Gotham City Research has just issued a report on Grifols - The report says that the company has manipulated its reported debt and EBITDA to artificially reduce its leverage which it believes is closer to 10x-13x net debt/EBIDTA. While the report flags some known facts there a number of issues related to the relationship between Grifols and Scranton (Grifols family vehicle) that we would like to study and discuss with the company as this could alter our investment ca...

Juan Ros-Padilla
  • Juan Ros-Padilla

Grifols B : Grifols delivers the SRAAS disposal right at the year-end

>Agreement with Haier to sell 20% of Shanghai Raas for $1.8bn - Grifols has reached a strategic alliance and share purchase agreement with Haier for the sale of a 20% equity stake in SRAAS in exchange for RMB 12.5bn (c.$ 1.8bn), while retaining a stake in SRAAS of 6.58%. The completion of the transaction is subject to customary regulatory approvals and the buyer's confirmatory due diligence. The current commercial strategic collaboration arrangements between Grifols ...

Juan Ros-Padilla
  • Juan Ros-Padilla

Grifols B : Q3 EBITDA in line with our numbers. Guidance nuanced to th...

>Plasma collection grows at a high-single-digit pace while its unit cost keeps falling - Q3 group sales grew by +4% or +9% cc (vs +9% cc in Q2) reaching € 1.6bn, broadly in line with our numbers and the consensus. Biopharma posted a robust +8% y-o-y growth or +14% cc (vs +10% cc in Q2) to € 1.4bn driven by: i/ solid plasma collection growth (+10% in 9M vs +12% in H1), ii/ IGg demand (higher Xembify demand in the US and robust IGg demand in Europe/ROW) and price uptick...

Baptiste Lebacq ... (+4)
  • Baptiste Lebacq
  • Emmanuel Matot
  • Jerôme Bodin
  • Marc Lavaud

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/10/2023

Sans direction depuis avril, les marchés européens sont récemment entrés dans une phase de bear market qui pourrait atteindre 5% supplémentaires d’ici fin 2023. Nous restons surpondérés sur les actions américaines vs européennes en raison de la résilience de l’économie US. En Europe, nous continuons de préférer les valeurs défensives peu endettées et leur adjoignons désormais celles du style Qualité. Nous ajustons notre allocation sectorielle tout en maintenant sa philosophie d’ensemb...

Juan Ros-Padilla
  • Juan Ros-Padilla

Grifols B : Q3 preview: lower cost per litre start to surface driving ...

>Cheaper plasma sourcing starts surfacing in the P&L driving margins to expand both q-o-q and y-o-y - The company is due to publish its Q3 2023 results on 2 November before the market opens. We expect sales to improve +4% y-o-y to € 1.6bn which implies some sequential top-line momentum deterioration (vs +8% in Q2 and +23% in Q1) as the company faces quite a hard comp (+37% in Q3 2022). At the EBITDA level, we expect a much faster pace (+17%) as the lower plasma sourci...

Baptiste Lebacq ... (+4)
  • Baptiste Lebacq
  • Emmanuel Matot
  • Jerôme Bodin
  • Marc Lavaud

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/20/2023

Without direction since April, European markets have recently entered a bear market phase that could extend by a further 5% out to the end of 2023. We remain overweight on US equities vs European equities due to the resilience of the US economy. We maintain our preference for defensive stocks with little debt, which we round out with a Quality positioning. We adjust our sector allocation whilst adhering to its overall philosophy: Short on debt & cyclicals, Long on attractive valuation...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch